Trial
NCT00077961
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Non-Hodgkin's Lymphoma
Intervention
CAMPATH (alemtuzumab)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-26